Ripple Therapeutics announced today that it entered into a deal with a Bausch + Lomb affiliate related to drug delivery technology. Toronto-based Ripple develops a patented technology platform based on drugs chemically engineered into controlled-release pharmaceuticals without the use of polymers. The proprietary prodrugs undergo surface erosion to give zero-order release kinetics. They are highly […]
Implants
Glucotrack now expects spring 2026 FDA IDE submission for implantable CGM
Glucotrack (Nasdaq:GCTK) today announced a slight delay in its plans to submit its long-term glucose monitor to the FDA for IDE. The company said in August that it expected a fourth-quarter investigational device exemption (IDE) submission for the long-term implantable continuous blood glucose monitor (CBGM). However, it says today that it anticipates a submission in […]
Vivani to initiate study of semaglutide implant in 2026
Vivani Medical (Nasdaq:VANI) today announced third-quarter earnings results that included timeline updates on its semaglutide implant. The Alameda, California-based company develops NanoPortal technology, which steadily delivers medication over extended periods of time. Vivani aims to guarantee correct patient doses while avoiding potential safety concerns around fluctuating drug release profiles. It can also deliver large hydrophilic […]
The top CGM stories of 2025
Millions of people worldwide are looking for ways to manage their diabetes. That’s where the continuous glucose monitor (CGM) comes in. The CGM market is expected to experience substantial, double-digit percentage growth over the next five years, reaching nearly $29 billion by 2030. Market leaders Abbott and Dexcom continue to establish their hold on the […]
Senseonics posts Q3 sales beat, expects CE mark for Eversense 365 this year
Senseonics (NYSE:SENS) shares ticked up after hours today on third-quarter results that beat the consensus sales forecast. Shares of SENS rose 2.1% to $6.87 apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $19.5 million. That equals 43¢ per share on sales of $8.1 million for […]
MIT engineers develop drug delivery patch for post-heart attack healing
Engineers at MIT say they developed a flexible drug delivery patch for promoting healing and tissue regeneration after heart attacks. The patch, placed on the heart after a heart attack, can help both heal and regenerate cardiac tissue. MIT said its engineers designed the patch to carry several different drugs capable of release at different […]
Vivani prices $15.7M offering
Vivani Medical (Nasdaq:VANI) announced that it priced a best efforts registered direct offering of 6 million shares of common stock. The Alameda, California-based company priced the shares at $1.62 apiece. It also announced a concurrent private placement of more than 3.7 million shares of common stock at the same price. Gregg Williams, the company’s board […]
Senseonics posts strong preliminary Q3 sales, reverse stock split
Senseonics (NYSE:SENS) today announced preliminary revenues for the third quarter and plans to conduct a reverse stock split. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker expects approximately $8.1 million in revenue for the third quarter of 2025. That marks a 91% uptick from the third quarter of 2024. The company attributed its growth […]
Elutia closes $88M bioenvelope sale to Boston Scientific
Elutia (Nasdaq:ELUT) announced today that it closed the $88 million sale of its bioenvolope technologies to Boston Scientific. Last month, the Gaithersburg, Maryland-based company announced an agreement to sell its EluPro and CanGaroo drug-eluting bioenvelopes to Boston Scientific in an all-cash deal. It designed these technologies to protect patients receiving implantable medical devices. With the […]
Vivani sets date for neuromod spin-off as focus turns to drug delivery implant
Vivani Medical (Nasdaq:VANI) announced today that it set a record date for the approved spin-off of its Cortigent subsidiary. In May, the Alameda, California-based company announced plans to spin off Cortigent, its division developing brain implants. The company wants to create two focused companies dedicated to driving current and future value in their respective therapeutic […]
